Recognized as one of the top medical care providers in the world, Taiwan has consistently been making strides in pharmaceuticals and biotech. Leading in its goal of developing cutting edge advances in oncology and ultimately providing quality healthcare is Dr ​​​​James Chih-Hsin Yang, director and professor at the Graduate Institute of Oncology and National Taiwan University, and director of the Department of Oncology at the National Taiwan University Hospital.

Dr Yang is a leader in lung cancer clinical studies, his work focusing on lung cancer treatment and the mechanism of multidrug resistance of chemotherapy. Along with other Asian researchers, he established Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKI) as the frontline treatment for lung cancer patients with EGFR mutation. He has also contributed to the approval of osimertinib, a targeted treatment option for lung cancer.

Yang recently received the Paul A. Bunn, Jr. Scientific Award 2022 for his lifetime achievement of scientific contributions to thoracic cancer research.